Log in

Pfenex Stock Forecast, Price & News

+0.05 (+0.39 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $12.75
50-Day Range N/A
52-Week Range
Now: $12.75
Volume1.48 million shs
Average Volume445,089 shs
Market Capitalization$437.29 million
P/E RatioN/A
Dividend YieldN/A
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.
Read More
Pfenex logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.91 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Previous SymbolNYSEMKT:PFNX



Sales & Book Value

Annual SalesN/A



Market Cap$437.29 million
Next Earnings Date11/5/2020 (Estimated)
+0.05 (+0.39 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Pfenex?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Pfenex

When is Pfenex's next earnings date?

Pfenex is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Pfenex

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) announced its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by $0.03. The biotechnology company had revenue of $0.78 million for the quarter, compared to analysts' expectations of $2.72 million.
View Pfenex's earnings history

What price target have analysts set for PFNX?

6 analysts have issued twelve-month target prices for Pfenex's shares. Their forecasts range from $13.00 to $19.00. On average, they anticipate Pfenex's stock price to reach $15.00 in the next year. This suggests a possible upside of 17.6% from the stock's current price.
View analysts' price targets for Pfenex

Are investors shorting Pfenex?

Pfenex saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 590,100 shares, a drop of 24.8% from the August 15th total of 785,100 shares. Based on an average daily trading volume, of 604,900 shares, the days-to-cover ratio is presently 1.0 days.
View Pfenex's Short Interest

Who are some of Pfenex's key competitors?

What other stocks do shareholders of Pfenex own?

Who are Pfenex's key executives?

Pfenex's management team includes the following people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 51)
  • Dr. Hubert C. Chen, Advisor (Age 50)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 55)

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

Who are Pfenex's major shareholders?

Pfenex's stock is owned by a number of retail and institutional investors. Top institutional investors include Blair William & Co. IL (8.87%), First Light Asset Management LLC (6.85%), RK Capital Management LLC (3.27%), Telemark Asset Management LLC (2.92%), Jacobs Levy Equity Management Inc. (0.83%) and Charles Schwab Investment Management Inc. (0.81%).
View institutional ownership trends for Pfenex

Which institutional investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., AQR Capital Management LLC, Falcon Point Capital LLC, Nuveen Asset Management LLC, Man Group plc, Delta Investment Management LLC, UBS Group AG, and ClariVest Asset Management LLC.
View insider buying and selling activity for Pfenex

Which institutional investors are buying Pfenex stock?

PFNX stock was purchased by a variety of institutional investors in the last quarter, including RK Capital Management LLC, Blair William & Co. IL, Telemark Asset Management LLC, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Bank of Montreal Can, Two Sigma Advisers LP, and Schonfeld Strategic Advisors LLC.
View insider buying and selling activity for Pfenex

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $12.75.

How big of a company is Pfenex?

Pfenex has a market capitalization of $437.29 million. Pfenex employs 71 workers across the globe.

What is Pfenex's official website?

The official website for Pfenex is www.pfenex.com.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.